Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Expanded NK Cells With Dinutuximab +/- Lenalidomide for Relapsed Refractory Neuroblastoma
NCT02573896Phase 1Active, not recruiting
- Sponsor
- New Advances in Neuroblastoma Therapy
- Start
- Jan 2019
- Primary completion
- Dec 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NK cell therapy (Anhui Provincial Hospital) in neuroblastoma, sponsored by New Advances in Neuroblastoma Therapy. Primary endpoints: NK cell production feasibility and Maximum Tolerated Dose / Recommended Phase 2 Dose. Started Jan 2019; status: active, not recruiting.
02
Drugs
NK cell therapy (Anhui Provincial Hospital)
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT02573896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573896.